MET Price Prediction Next Week
Technical Analysis
Based on the technical indicators, MET is showing mixed signals. The RSI(14) at 58.76 indicates a neutral momentum, not yet overbought. The MACD at 1.01 suggests a bullish trend momentum. The stock is trading above both its 20-day (83.53) and 60-day (83.08) moving averages, indicating an overall upward trend.
Fibonacci Analysis The Fibonacci levels show:
- Resistance 3: 92.59
- Resistance 2: 89.40
- Resistance 1: 87.43
- Pivot: 84.24
- Support 1: 81.05
- Support 2: 79.08
- Support 3: 75.89
News Impact Recent significant developments:
- MetLife Investment Management is acquiring three portfolio management teams from Mesirow, involving approximately $6 billion in assets. This strategic move should enhance their institutional asset management business.
- The company will announce Q4 earnings on January 29, with analysts expecting EPS of $2.17, a 12.4% increase from the previous year.
- The company's new 5-year Frontier Growth strategy aims to generate $25 billion in free cash flow.
Price Prediction for Next Week Based on technical and news analysis:
- Target Price: 87.40 (Fibonacci R1)
- Recommendation: BUY
- Rationale:
- Strong institutional business expansion through Mesirow acquisition
- Positive earnings expectations
- Trading above key moving averages
- Bullish MACD signal
- Strong analyst consensus with "Strong Buy" rating and average price target of $93.54
The stock is likely to test the first resistance level at 87.43 next week, supported by positive earnings expectations and recent strategic moves. The risk/reward ratio appears favorable with strong support at 81.05.
MET Similar Chart Price Prediction
The price of MET is predicted to go up 3.03%, based on the high correlation periods with RDY. The similarity of these two price pattern on the periods is 94.08%.
MET
RDY
Up: 3.03%Similarity: 94.08%
MET Revenue Forecast
MET EPS Forecast
MET FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
MET VS S&P500
MetLife's leading market positions in various international markets (particularly Asia and Latin America) provide opportunities for growth.
MetLife's strategy has reduced exposure to riskier products like variable annuities with minimum guarantees and has increased investments in segments with steadier cash flows like the group benefits business.
The company will be a net beneficiary of rising interest rates in the long run as it can reinvest its maturing fixed-income securities at a higher yield.
MET Analyst's Forecast
Jimmy Bhullar
JP Morgan
Buy
Price Target
$86 → $88
Upside
+7.13%
JPMorgan raised the firm's price target on MetLife to $88 from $86 and keeps an Overweight rating on the shares as part of a 2025 life insurance preview. The firm's long-term fundamental outlook for the life insurance sector is downbeat, but it remains bullish on stocks in the near term. The favorable macro backdrop, insurers' "healthy" balance sheets and flexibility for share buybacks, and current valuations will enable life insurance stocks to outperform further, contends JPMorgan. It considers potential deterioration in corporate credit the key risk to its bullish stance.
Alex Scott
Barclays
Buy
Price Target
$90 → $96
Upside
+17.09%
Daniel Bergman
TD Cowen
Strong Buy
Price Target
$97 → $99
Upside
+12.18%